Bristol-Myers Squibb (BMY) Tops Q3 EPS by 30c, provides guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.80, $0.30 better than the analyst estimate of $1.50. Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.26 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2024 EPS of $0.75-$0.95, versus the consensus of $0.71.
Revenues are expected to be ~5% increased over the prior guidance of Upper end of low single-digit range

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• DeFi Technologies posts $7.8M revenue and $2.3M loss in Q2 2026